Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With... | NCT00231517 | Trialant
CompletedInterventionalPhase 4Updated Oct 12, 2006
Randomised Double Blind Placebo Controlled Cross Over Design of the Efficacy of Topical Morphine for Inflammatory Pain in Children With Epidermolysis Bullosa
ClinicalTrials.gov ID
NCT00231517
Lead Sponsor
Institute of Child HealthOTHER
Overall Status
Completed
Study Type
Interventional
Phase
Phase 4
Last Update Posted
Oct 12, 2006Estimated
Brief Summary
Randomised Double blind placebo controlled cross over design study of the efficacy of morphine for inflammatory pain in children with Epidermolysis Bullosa
Epidermylosis Bullosa
topical opiod
morphine sulphate in intrasite gel
Ages Eligible for Study
Child (0-17)Adult (18-64)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
children under 18 years epidermolysis wounds requiring dressing changes
Primary Purpose
Treatment
Allocation
Randomized
Interventional Model
Crossover Assignment
Masking
Double
No central contacts
There are no central contacts for this study.
Great Ormond Street Hospital and the Institute of Child health